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ABSTRACT
Purpose: The product of the carcinoembryonic antigen
(CEA) gene is an attractive candidate for T-cell-based im-
munotherapy because it is frequently expressed in epithelial
solid carcinomas. Although many CEA peptide epitopes
capable of stimulating CTLs have been identified, no MHC
class II-restricted T helper epitope has yet been reported.
Experimental Design: The amino acid sequence of CEA
was examined for the presence of potential T helper
epitopes, and candidate peptides were used to stimulate in
vitro T-cell responses.
Results: We describe here that using an algorithm to
identify promiscuous helper T-cell epitopes, a peptide of
CEA occupying residue positions 653 to 667 (CEA653–667),
was effective in inducing in vitro T helper responses in the
context of the HLA-DR4, HLA-DR7, and HLA-DR9 alleles.
Most significantly, some of the peptide-reactive helper T
lymphocytes were also capable of recognizing naturally pro-
cessed antigen in the form of recombinant CEA protein or
cell lysates from tumors that express CEA. Interestingly, the
newly identified helper T-cell epitope was found to overlap
with a previously described HLA-A24-restricted CTL
epitope, CEA652–660, which could facilitate the development
of a therapeutic vaccine capable of eliciting both CTL and T
helper responses in patients suffering from epithelial carci-
nomas.
Conclusion: These results indicate that T helper lym-
phocytes are capable of recognizing CEA as a tumor antigen
and that epitope CEA653–667 could be used for immunother-
apy against tumors expressing CEA.
INTRODUCTION
CEA3 is an Mr 180,000 glycoprotein that is an ideal TAA
for the development of immunotherapy because it is produced
by most colorectal, gastric, and pancreatic carcinomas (1). Fur-
thermore, CEA is abundantly expressed by 50% of breast cancer
and 70% of non-small cell lung carcinomas (2). Several proteins
from the CEA gene family such as NCA and BGP are expressed
in the normal cells (e.g., neutrophils and granulocytes) and share
regions of identical sequence with CEA (2). Moreover, CEA is
also present (although at usually much lower concentrations) in
the normal colon epithelium and in some fetal tissues. There-
fore, CEA does not constitute tumor-specific antigen, creating
concerns that it might either induce pathogenic immune re-
sponses to normal cells (i.e., autoimmunity) or, alternatively, be
nonimmunogenic because of immune tolerance.
The design and implementation of T-cell-based immuno-
therapy for cancer relies heavily in the identification of immu-
nogenic T-cell peptide epitopes from TAAs capable of eliciting
antitumor responses. Because MHC class I-restricted CTLs have
a direct lytic effect on tumor cells, most efforts have focused on
the identification of peptide epitopes capable of stimulating
these types of responses. As a consequence, numerous CTL
epitopes from CEA have been described, which were found to
be restricted by commonly found MHC class I alleles such as
HLA-A2, -A3, -A24, -B7, and -B27 (3–10). Therefore, the
identification of CTL epitopes for CEA has opened the door to
the development of epitope-based immunotherapy for CEA-
expressing tumors.
Because HTLs play an important role both in the induction
and maintenance of CTL responses, vaccines that activate both
CTLs and HTLs should be more effective than vaccines that
only target CTL responses (11). Experiments in animal model
systems have demonstrated the importance of antigen-specific
HTLs in the elimination of tumors by CTLs (12–16). Moreover,
using an in vitro model of human antitumor rejection mediated
by CTLs, we reported recently that the presence of HTLs was
critical for the eradication of the tumor cells (17). These exper-
iments demonstrated that only in the presence of HTLs were the
CTLs able to expand during the effector phase of the immune
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response, resulting in an increase in the overall antitumor cyto-
lytic activity. In view of this, one obvious way to improve
vaccines designed to induce antitumor CTLs is to include in
these vaccines MHC class II-restricted epitopes that would
trigger HTL responses to TAAs. In agreement with this assess-
ment, several groups including ours have devoted considerable
efforts to defining T-helper epitopes for various TAAs such as
tyrosinase, gp100, MART1/Melan-A, NY-ESO-1, p53, and
HER2/neu (18–29). In some of these cases, the identified HTL
epitopes were found to be highly promiscuous with regard to
their MHC class II restriction, which would allow their use in
large patient populations.
In the present study, we used a computer-based algorithm
(30) to identify peptide sequences from CEA with potential
promiscuous MHC class II binding characteristics. Using this
approach, we selected peptide CEA653–667, which was found to
be effective in generating in vitro HTL responses restricted by
the HLA-DR4, -DR7, and -DR9 alleles. More importantly, some
of the peptide-generated HTLs were also capable of recognizing
naturally processed antigen in the form of recombinant CEA
protein or cell lysates prepared from CEA-positive tumors. The
present findings should hold some value for the development of
epitope-based vaccines to elicit CTL and HTL responses against
CEA-expressing tumors.
MATERIALS AND METHODS
Cell Lines. EBV-LCLs were produced from PBMCs of
HLA-typed volunteers using culture supernatant from the EBV-
producing B95-8 cell line. Mouse fibroblast cell lines (L-cells)
transfected and expressing individual human MHC class II
molecules were kindly provided by Dr. R. W. Karr (Pfizer
Global R&D, New London, CT) and by Dr. T. Sasazuki
(Fukuoka, Japan). The colon adenocarcinoma cell line SW403,
the Jurkat T-cell lymphoma, and the IL-2-dependent CTLL cell
line were purchased from American Type Culture Collection
(Manassas, VA). The colon carcinoma cell line WiDr was
supplied by the Japanese Cancer Research Resources Bank
(Tokyo, Japan).
Synthetic Peptide and Recombinant Antigens. Poten-
tial HLA-DR promiscuous CD4 T-cell epitopes were selected
from the amino acid sequence of CEA using the algorithm tables
for three HLA-DR alleles (DRB1*0101, DRB1*0401, and
DRB1*0701) described by Southwood et al. (30). The selected
peptide, CEA653–667 (YACFVSNLATGRNNS), which dis-
played high algorithm scores, was synthesized by solid phase
organic chemistry and purified by high-pressure liquid chroma-
tography. The purity (80%) and identity of peptide were
assessed by high-pressure liquid chromatography. Recombinant
CEA protein was purchased from Sigma Chemical Co. (St.
Louis, MO). Recombinant Hpcal 1 was expressed in Esche-
richia coli as a glutathione S-transferase-fusion protein. The
Hpcal 1 protein was concentrated, and the purity of the protein
was verified by SDS-PAGE.
In Vitro Induction of Antigen-specific HTL Lines
with Synthetic Peptide. The procedure selected for the
generation of tumor antigen-reactive HTL lines using pep-
tide-stimulated PBMCs has been described in detail (21–23).
Briefly, DCs were produced in tissue culture from adherent
monocytes that were cultured for 7 days at 37°C in a humid-
ified CO2 (5%) incubator in the presence of 50 ng/ml gran-
ulocyte/macrophage-colony stimulating factor and 1000
IU/ml IL-4. Peptide-pulsed DCs (3 g/ml for 2 h at room
temperature) were irradiated (4200 rad) and cocultured with
autologous purified CD4 T cells (using antibody-coated
magnetic microbeads from Miltenyi Biotech, Auburn, CA) in
round-bottomed, 96-well culture plates. One week later, the
CD4 T cells were restimulated with peptide-pulsed irradi-
ated autologous PBMCs, and 2 days later, human recombi-
nant IL-2 was added at a final concentration of 10 IU/ml. One
week later, the T-cells were tested for their proliferative
responses to peptide as described below. Those cultures
exhibiting a proliferative response to peptide (at least 3-fold
over background) were expanded in 24- or 48-well plates by
weekly restimulation with peptides and irradiated autologous
PBMCs. Complete culture medium for all procedures con-
sisted of RPMI 1640 supplemented with 5% human male AB
serum, 0.1 mM MEM nonessential amino acids, 1 mM sodium
pyruvate, 2 mM L-glutamine, and 50 g/ml gentamicin. The
Institutional Review Board on Human Subjects (Mayo Foun-
dation) approved this research, and informed consent for
blood donation was obtained from all volunteers.
Measurement of Antigen-specific Responses with HTL
Lines. CD4 T cells (3  104/well) were mixed with irradi-
ated APCs in the presence of various concentrations of antigen
(peptides, recombinant proteins, or tumor lysates) in 96-well
culture plates. APCs consisted of either PBMCs (1  105/well),
HLA-DR-expressing L-cells (3  104/well), EBV-LCLs (3 
104/well), or DCs (5  103/well). Tumor cell lysates were
prepared by three freeze-thaw cycles of 1  108 tumor cells,
resuspended in 1 ml of serum-free RPMI 1640. Lysates were
used as a source of antigen at 5  105 cell equivalents/ml.
Culture supernatants were collected after 48 h for measuring
antigen-induced lymphokine (granulocyte/macrophage-colony
stimulating factor) production by the HTLs using ELISA kits
(PharMingen, San Diego, CA). Cell proliferation assays were
incubated at 37°C for 72 h, and during the final 16 h, each well
was pulsed with 0.5 Ci/well of [3H]thymidine (Amersham
Pharmacia Biotech, Piscataway, NJ). The radioactivity incorpo-
rated into DNA, which correlates with cell proliferation, was
measured in a liquid scintillation counter after harvesting the
cell cultures onto glass fiber filters. To determine MHC
restriction molecules involved in antigen presentation, block-
ing of the antigen-induced proliferative response was inves-
tigated by adding anti-HLA-DR monoclonal antibody L243
(IgG2a, prepared from supernatants of the hybridoma HB-55
obtained from the American Type Culture Collection; Ref.
31) or anti-HLA-A, -B, -C monoclonal antibody W6/
32(IgG2a, American Type Culture Collection). To evaluate
the effect of antigen-specific antibodies on the response of
HTLs to CEA, we added anti-CEA monoclonal antibody
MD06 (IgG1; Takara, Otsu, Japan). All antibodies were used
at a final concentration of 10 g/ml throughout the 48-h
incubation period. All assessments of proliferative responses
or ELISA were carried out at least in triplicate, and results
correspond to the mean values with the SD of the mean.
3220 A Helper T-Cell Epitope for CEA
 American Association for Cancer Research Copyright © 2002 
 on April 4, 2012clincancerres.aacrjournals.orgDownloaded from 
RESULTS
Selection of Potential HTL Epitopes for CEA. Because
our goal was to identify promiscuous MHC class II HTL
epitopes for CEA, we first examined the amino acid sequence of
this TAA for the presence of peptides containing binding motifs
for HLA-DRB1*0101, DRB1*0401, and DRB1*0701 (referred
to as HLA-DR1, -DR4, and DR7 in the remaining text of this
work), which are commonly found in the general population.
The binding motifs that we used are based on the algorithm
values described by Southwood et al. (30), which calculate the
potential (predicted) binding interactions of primary and sec-
ondary anchors of a 9-amino acid “core region” for each of the
three MHC class II alleles. This approach has been very suc-
cessful in our hands, allowing us to identify several promiscuous
HTL epitopes from TAAs such as HER2/neu, gp100, and
MAGE-A3 (21–23). The four highest ranking, potentially pro-
miscuous core sequences that were identified using this method
were CEA97–110, CEA116–130, CEA653–667, and CEA665–679.
The amino acid sequences of CEA97–110 and CEA116–130 are
almost identical (only one amino acid difference) to the se-
quence found on the two closely related proteins of CEA, BGP,
and NCA, which are widely expressed throughout the organism.
Thus, we decided not to select these epitopes for further analysis
because of the possibility of the existence of immune tolerance
or, alternatively, concerns of inducing generalized autoimmune
toxicity. The potential HTL epitope CEA665–679 is destroyed
during posttranslational modification of the CEA protein by
protease cleavage at position 676 (32, 33), creating the uncer-
tainty of whether this peptide will exist in sufficient amounts in
APCs to function as an HTL epitope. On the other hand, the
sequence represented by peptide CEA653–667 was found to be
present in CEA and not in BGP or NCA, making it an attractive
candidate as a promiscuous epitope for tumor-reactive HTLs.
We thus decided to focus our efforts in peptide CEA653–667 to
evaluate whether it could be capable of inducing antigen-
specific HTL responses after in vitro T-cell immunization.
T-Cell Responses to a Peptide Epitope from CEA.
Peptide CEA653–667 was synthesized and tested for its ability to
stimulate T-cell responses using PBMCs isolated from four
healthy, MHC class II-typed individuals (HLA-DR1/13, HLA-
DR4/15, HLA-DR4/9, and HLA-DR7/17). Purified CD4 T
cells were stimulated in primary cultures using peptide-pulsed
autologous DCs as APCs, as described in “Materials and Meth-
ods.” After three to four cycles of peptide restimulation using
autologous irradiated PBMCs as APCs, the lymphocyte cultures
were then tested for their capacity to respond to the peptide
presented by autologous PBMCs as APCs. Those cultures that
exhibited at least a 3-fold increase of proliferative response to
peptide (data not shown) were selected and expanded for further
analyses. For 3 of the 4 individuals, HTL lines were obtained
and analyzed for their MHC restriction patterns. In the case of
the DR4/DR9 individual, significant T-cell responses to peptide
CEA653–667 were observed when autologous PBMCs were used
as APCs, which could be inhibited to a great extent by anti-
HLA-DR antibodies but not by anti-MHC class I antibodies
(Fig. 1a). These T cells did not respond significantly to an
irrelevant peptide (data not shown). When mouse fibroblasts
(L-cells) transfected with HLA-DR4, -DR9, or -DR53 were
used as APCs, the HTLs from this individual recognized peptide
CEA653–667 only when presented by the L-DR9 cells (Fig. 1b).
To evaluate the overall affinity (avidity) of the HLA-DR9-
restricted HTLs for its ligand, peptide titration curves were
performed using various types of autologous APCs (DCs, PB-
MCs, and EBV-LCLs) and L-DR9 cells. These results show that
the HTL line displayed high avidity for peptide CEA653–667
because 1 g/ml of peptide was required to attain 50% of
maximal response when autologous DCs, PBMCs, or EBV-
LCLs were used as APCs (Fig. 1c). These results also indicate
that although DCs were the most potent type of APCs, requiring
10 ng/ml of peptide to produce 50% of maximal response, the
L-DR9 cells were 200-fold less potent as APCs, possibly
because of the lack of human adhesion molecules.
From the DR4/15 and DR7/17 individuals, HTL cultures
were obtained, which proliferated to peptide CEA653–667 pre-
sented by L-DR4 and L-DR7 APCs, respectively (Fig. 2), indi-
cating that this epitope has some degree of promiscuity. How-
ever, these HTLs did not expand sufficiently to allow us to
conduct additional experiments. Lastly, peptide CEA653–667
was unable to trigger T-cell responses in the HLA-DR1/DR13
individual (data not shown).
Recognition of Processed Tumor Antigens by
CEA653– 667-reactive HTLs. The results presented above
indicate that the peptide CEA653– 667 was indeed capable of
inducing CD4 T-cell responses. However, it is important to
determine whether the peptide-reactive T cells are capable of
recognizing the naturally processed antigen, in this case, the
CEA protein. Thus, APCs (DCs or monocytes) that capture
the CEA protein (or cell lysates from CEA tumors) would
be expected to process the antigen to produce a peptide
corresponding to CEA653– 667 (or a closely related species),
which would bind to MHC class II molecules to be presented
to the T cells. Only under these circumstances can one be
certain that the predicted T-cell epitope will be biologically
relevant for developing immunotherapy against CEA-
expressing tumors. Consequently, we first proceeded to test
the capacity of the HLA-DR9-restricted, CEA653– 667-specific
T-cell line to recognize naturally processed antigen in the
form of recombinant CEA protein. As shown in Fig. 3a, the
CEA653– 667-reactive T-cell line responded well to recombi-
nant CEA protein but not to a control antigen, recombinant
Hpcal 1, when autologous DCs were used as APCs. These
results demonstrate that the epitope represented by peptide
CEA653– 667 is produced by the antigen-processing pathway
occurring on APCs. Because it would be more significant to
assess whether the APCs will capture antigen derived from
dead tumor cells expressing CEA and appropriately present
the epitope to the HTLs, we examined this possibility. The
CEA653– 667-reactive HTLs were evaluated for their capacity
to recognize naturally processed tumor antigen using DCs
that were fed with dead CEA-expressing tumor cells (in this
case, freeze/thaw cell lysates). The data presented in Fig. 3b
demonstrate that the CEA653– 667-reactive T-cell line was
able to respond in a dose-dependent manner to DCs present-
ing cell lysates from two CEA-positive tumors (SW403 and
WiDr) but not with DCs presenting a lysate from a CEA-
negative T-cell lymphoma (Jurkat).
The capacity of the HTLs to recognize naturally processed
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CEA in the form of tumor lysates presented by DCs was
inhibited by anti-HLA-DR antibodies (but not by anti-MHC
class I antibodies), confirming that the processed T-cell epitope
represented by CEA653–667 was presented in the context of
MHC class II molecules (Fig. 4). Furthermore, the T-cell re-
sponses to the tumor lysates were substantially enhanced by the
addition of anti-CEA antibodies (Fig. 4), which presumably
increases the delivery of antigen to the APCs via the formation
of immune complexes that are captured through surface Fc
receptors (34, 35). The enhancement by the anti-CEA antibodies
was antigen specific because no effects were observed when
lysates from CEA-negative tumors (Jurkat) were used.
Fig. 1 HLA-DR9-restricted T-cell responses to peptide CEA653–667. An HTL line was selected from an HLA-DR4/DR9 normal individual by weekly
stimulation of CD4 T cells with peptide and APCs as described in “Materials and Methods.” Using autologous PBMCs as APCs (a), the T-cell
response to peptide CEA653–667 was inhibited by anti-HLA-DR monoclonal antibodies (DR abs, L243 at 10 g/ml) but not by anti-MHC class I
antibodies (MHC CI abs, W6/32 at 10 g/ml). When mouse fibroblasts transfected with human HLA-DR genes were used as APC (b), it became
evident that the HTL line recognized peptide CEA653–667 (used at 3 g/ml) in the context of HLA-DR9. Peptide dose-curve responses were performed
to estimate the overall avidity of the HTLs for peptide CEA653–667 using various types of APCs (c). Dashed lines, the peptide concentration required
to obtain 50% of the maximal response (0.01 g/ml with DCs, 0.05 g/ml with PBMCs, 0.2 g/ml with EBV-LCLs, and 2.0 g/ml with
L-DR9 cells). Values shown are the means of triplicate determinations; bars, STD. Columns and symbols without bars have SDs too small to appear
in the figure.
Fig. 2 HLA-DR4 and -DR7-resric-
ted T-cell responses to peptide
CEA653–667. HTL lines were selected
from DR4/15 (a) and DR7/17 (b) nor-
mal donors by weekly stimulation of
CD4 T cells with peptide and APCs.
Results represent the peptide-induced
proliferative responses to 3 g/ml of
CEA653–667 in the presence of various
types of irradiated APCs. Values
shown are the means of triplicate sam-
ple; bars, STD. Columns without error
bars have SDs too small to appear in
the figure.
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DISCUSSION
Although numerous CEA epitopes for MHC class I-
restricted CTLs have been identified (3–10), to our knowledge
this is the first report of a peptide epitope capable of stimulating
MHC class II-restricted HTL responses. This epitope was dis-
covered using a computer-based algorithm (30) that has also
enabled us to identify HTL epitopes from other TAAs such as
HER2/neu, gp100, and MAGE3 (21–23). Although the epitope
represented by peptide CEA653–667 was selected on the basis of
potentially being a peptide capable of binding to HLA-DR1,
-DR4, and -DR7, the T-cell responses induced by this peptide in
our present studies were found to be restricted by HLA-DR4,
-DR7, and -DR9. From the limited number of experiments done
here, we cannot exclude the possibility that peptide CEA653–667
will not induce HLA-DR1-restricted T-cell responses. The ob-
servation that HLA-DR9-restricted responses were produced by
peptide CEA653–667 is not unexpected because we and others
have observed that peptides predicted to be promiscuous
epitopes using the “Southwood algorithm” in many cases extend
their restriction capacity beyond the three alleles (HLA-DR1,
-DR4, and -DR7) that are considered by this algorithm (21, 22,
30, 36). Epitopes identified by this method have been found to
be presented by numerous alleles such as HLA-DR1, -DR4,
-DR7, -DR9, -DR11, -DR13, -DR15, -DR16, -DR51, -DR52,
-DR53, -DQ2, -DQ6, or -DQ7. Moreover, peptide CEA653–667
also scored high using a predictive algorithm for promiscuous
MHC class II binders that we have developed (data not shown;
Ref. 37). Thus, it is probable that peptide CEA653–667 could be
recognized by HTLs in the context of additional alleles besides
HLA-DR4, -DR7, and -DR9, but experimental data will be
required to test such possibility.
Recognition of naturally processed antigen is a hallmark
that the predicted epitope will be relevant for vaccine/immuno-
therapy development. In many cases, peptide-reactive HTLs are
not capable of recognizing APCs that ingest and process the
antigen into MHC class II-binding peptides. Possibilities for the
lack of recognition of naturally processed antigen by peptide-
reactive T cells could be: (a) presence of partially deprotected
peptide impurities, which could be very immunogenic; (b) the
destruction of the corresponding peptide if it is cleaved inap-
propriately by proteases during processing (i.e., “cryptic
epitopes”); and (c) insufficient density of specific MHC peptide
complexes on the surface of the APCs to allow T-cell activation.
The last possibility could be the result of low amounts of CEA
protein captured by the APCs or if the peptide does not bind
with sufficient affinity to the MHC molecule to generate stable
peptide/MHC complexes. The data presented herein demon-
strate that, at least in the case of T-cell responses to peptide
CEA653–667 that are restricted by HLA-DR9, the HTLs were
quite effective in recognizing naturally processed CEA in the
form of recombinant protein or cell lysates from CEA tumors.
Although it seems reasonable that the HLA-DR4- and -DR7-
restricted HTLs would also recognize the naturally processed
CEA epitope, this possibility could not be assessed because the
T-cell lines were not sufficiently stable to allow us to carry out
these determinations.
Interestingly, the newly identified HTL CEA epitope was
found to overlap with the previously described HLA-A24-
restricted CTL epitope, CEA652–660 (7), which would allow the
Fig. 3 Recognition of naturally processed anti-
gen by the HLA-DR9-restricted CEA653–667-
specific HTL line. Using autologous DCs as
APCs, the peptide-induced HTLs were able to
recognize recombinant CEA protein (a) or various
amounts of cell lysate from tumors expressing
CEA (b). Values shown are the means of triplicate
determinations; bars, SD. Columns and symbols
without error bars have SDs too small to appear in
the figure.
Fig. 4 Antibody-mediated blocking or enhancement in the responses
of HTL to naturally processed antigen. Using autologous DCs as APCs,
the effect of antibodies specific for HLA-DR (DR abs), MHC class I
(MHC CI abs), or CEA (CEA abs) were evaluated in the response of
the HLA-DR9-restricted HTL to lysates from SW403 (CEA), WiDr
(CEA), or Jurkat (CEA). Values shown are the means of triplicate
determinations; bars, SD. Columns without error bars have SDs too
small to appear in the figure.
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use of a relatively small peptide (CEA652–667) as a vaccine
designed to elicit both CTL and HTL responses in some indi-
viduals. Such a vaccine would be quite useful in the Japanese
population, where HLA-A24, -DR4, and -DR9 are common
MHC alleles.
In addition to potentially being a promiscuous HTL
epitope, we deliberately selected the CEA653–667 sequence be-
cause it was absent in BGP and NCA. This decision served two
purposes: (a) we were concerned that peptides corresponding to
CEA sequences that are identical (or similar) to BGP or NCA
would not be immunogenic because immune tolerance is likely
to exist to widely expressed proteins such as BGP and NCA; and
(b) most importantly, we wanted to diminish the chances of
inducing serious autoimmune pathology if a vaccine containing
a cross-reactive T-cell epitope would be effective in overcoming
immune tolerance because BGP and NCA are widely expressed
in various tissues. Nevertheless, we are conscious that a vaccine
based on peptide CEA653–667 could still induce autoimmune
pathology because CEA is expressed in small amounts in the
gut. However, because no reports of serious adverse events have
occurred in numerous vaccine studies using CEA as a TAA
(38–46), we are strongly hopeful that a therapeutic vaccine for
tumors expressing CEA, which incorporates the HTL epitope
identified here, would increase the chances of inducing effective
and long-lasting immune responses that may lead to clinical
benefit.
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